Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mudit Sharma

Neurological Surgery Manassas, VA Medical Doctor

NPI 1285700369 CMS profile 12984

9625 Surveyor Court, Suite 320, Manassas, VA 20110

Open in the dashboard

General payments

$713,609

397 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mudit Sharma of Manassas, VA is reported in the CMS Open Payments database as having received $713,609 across 397 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $121,176 36
2024 General $95,223 46
2023 General $110,022 50
2022 General $123,155 78
2021 General $94,382 91
2020 General $88,017 55
2019 General $81,633 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mudit Sharma
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Mudit Sharma were reported at $121,176. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Mudit Sharma Neurological Surgery median Middle half National median
2019 $81,633 $582 $138–$3,006 $163
2020 $88,017 $294 $76–$2,174 $114
2021 $94,382 $387 $105–$2,432 $132
2022 $123,155 $542 $139–$2,989 $149
2023 $110,022 $534 $145–$2,697 $160
2024 $95,223 $574 $155–$3,046 $164
2025 $121,176 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Spineart SA $530,650 22 payments
  2. Spineart USA Inc $136,411 123 payments
  3. Spine Wave, Inc. $14,409 28 payments
  4. 4WEB, Inc. $11,793 9 payments
  5. Stryker Corporation $10,665 115 payments
  6. Centinel Spine, LLC $3,943 6 payments
  7. Abbott Laboratories $2,102 64 payments
  8. Medtronic, Inc. $1,262 13 payments
  9. HD LifeSciences LLC $375 1 payment
  10. Innovasis Inc $354 2 payments
  11. Other $1,644 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $529,029 14 payments
  2. Consulting Fee $92,274 35 payments
  3. Travel and Lodging $64,860 67 payments
  4. Food and Beverage $27,244 280 payments
  5. Entertainment $201 1 payment
Products named General payments · program years 2019–2025
  1. SCARLET AL-T - SECURED LUMBAR ANTERIOR CAGE Orthopedic $208,519 10 payments
  2. SCARLET AL-T - SECURED LUMBAR ANTERIOR CAGE Devices $102,866 2 payments
  3. PERLA C $76,007 2 payments
  4. Scarlet AL-T Orthopedic Surgery $39,665 2 payments
  5. Scarlet AC Orthopedic Surgery $39,665 2 payments
  6. JULIET LL - LATERAL CAGE PEEK $38,434 1 payment
  7. PERLA TL $38,109 29 payments
  8. Scarlet AL-T Orthopedics $32,599 1 payment
  9. Scarlet AC Orthopedics $31,651 1 payment
  10. SCARLET AL-T Orthopedic $16,212 18 payments
  11. Other $62,560 261 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

87

Median for Neurosurgery: 83

Drug cost

$369

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 22 $181
Cyclobenzaprine Hcl Generic 23 $76
Tizanidine Hcl Generic 11 $54
Dexamethasone Generic 17 $41
Meloxicam Generic 14 $16

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$357,251

Medicare's payments for the services billed

Medicare patients

258

Average age 73

Services billed

860

150 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 38%
Diabetes 36%
Depression 29%
Chronic kidney disease 22%
COPD 19%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

397 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record